

Long-term immunosuppressive treatment in immune-mediated neuromuscular diseases: data of a multicentric retrospective observational study

M Garnero¹, C Gemelli¹, C Demichelis¹, M Grandis¹, A Beronio², E Giorli², M Maestri³, I Callegari⁴, A Cortese⁴, C Comi⁵, E Virgilio⁵, A Schenone¹, L Benedetti¹

University of Genova¹, Sant'Andrea Hospital-La Spezia², University of Pisa³, C Mondino National Neurological Institute-Pavia⁴, University of Piemonte Orientale 'Amedeo Avogadro`-Novara⁵

Introduction

The long-term use of immunosuppressive agents in immune-mediated neuromuscular diseases is currently not standardized and their utilization, in most cases, is individualized for each center and based on clinical experience.

Methods

Multicentric retrospective observational study.

The patients enrolled have been treated with benefit, for at least one year, with a "classic" immunosuppressive agent.

70 patients included

23 CIDP and variants
37 Myasthenia Gravis
4 Inflammatory Myopathies
3 Vasculitis of the PNS
2 Multifocal Motor Neuropathies
1 Stiff person syndrome

Results and Discussion

Immunosuppressive drugs


| Azathioprine | 64.7% |
|-----------------------|-------|
| Cyclophosphamide | 17.6% |
| Mycophenolate Mofetil | 10.6% |
| Cyclosporine | 3.5% |
| Methotrexate | 3.5% |

Continuation of drugs:

Average of treatment 5.4 years (51.4%)

Discontinuation of drugs: causes

Adverse events (21.4%)
Relapses (12.9%)
Clinical stability (10%)
Drug maximum cumulative dosage (4.3%)



Adverse events


Squamous cell skin cancer
Lung cancer
Urothelial cancer
Post herpetic neuritis
Pancytopenia
Megaloblastic anemia



One patient died of lung cancer

Discontinuation of drugs: consequences

Acute Relapse 47,1% Clinical stability 38,2% Progressive worsening 14,7%



Rebound management

Steroids
Intravenous immunoglobulins
Plasmapheresis
Immunosuppressive drugs

Conclusions

The most frequently used immunosuppressive drug in immune-mediated neuromuscular diseases is <u>Azathioprine</u> (64,7%)

In most of cases the long-term use of immunosuppressive drugs resulted in a <u>clinical remission</u>, unfortunately, this <u>not always coincides with a real remission of the disease</u> and the discontinuation of the drug is frequently followed by clinical relapse

Further studies are necessary in order to define general recommendations about the management of these treatments

